The top Democrat in the Florida Senate filed a bill on Friday that would require the state to research the medical benefits of psychedelics such as psilocybin and MDMA.
If enacted, the state Department of Health would be directed to “conduct a study evaluating the therapeutic efficacy of alternative therapies” such as those substances, as well as ketamine, “in treating mental health and other medical conditions,” including depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, chronic pain and migraines.
The proposal, sponsored by Senate Minority Leader Lauren Book (D) is modeled on legislation enacted into law in Texas earlier this year that similarly instructs officials in that state to research the therapeutic value of certain psychedelics, although that bill had a narrower focus on helping military veterans with PTSD.
A companion version of the Florida measure is being carried in the House by Rep. Michael Grieco (D).
“This is one of the rare times it would be ok to Texas our Florida, since the Lone Star State is one of many who embrace the FDA’s breakthrough designation for alternate mental health therapies such as psilocybin,” Grieco told Marijuana Moment. “This bill will send our state in the right direction, especially amongst our veterans, for patients who are resistant to traditional mental health therapies.”
Proud to work with @Mike_Grieco on this important piece of legislation; that will help individuals living with PTSD have a natural pathway to wellness. https://t.co/kqbocsF2Od
— Lauren Book (@LeaderBookFL) September 25, 2021
Book said in a press release that the legislation “provides a natural pathway to wellness for patients with debilitating post-traumatic stress disorder and treatment-resistant depression.”
“Psilocybin treatment is a safe alternative for those who have exhausted all other avenues for mental health and wellbeing, and I am proud to sponsor legislation to ensure Floridians have medical access to this life-saving natural treatment,” she said.
Grieco added in the release that “Florida does not have to be the last state to catch up with science every time.”
“Between medical marijuana and climate change, our state seems to never miss an opportunity to miss an opportunity,” he said. “The science regarding psilocybin is real, cannot be ignored, and soon will be a universally-accepted form of treatment in the U.S. Veterans and veterans organizations should be watching closely on behalf of folks suffering from addiction, PTSD and depression.”
—
Marijuana Moment is already tracking more than 1,200 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
The governor of Connecticut signed a bill in June that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
Under the Florida legislation—SB 348 and HB 193—officials would have to submit a report and recommendations to the governor and top lawmakers by September 1, 2023.
Earlier this year, Grieco filed a more far-reaching bill that would have created a broader program of legal access to psilocybin for therapeutic use, similar to the ballot measure approved by Oregon voters last year. That legislation failed to advance through committee, however.
“After authoring a very ambitious 59-page bill last year, one that started a broader conversation,” Grieco said, “I am ready to work with both my Republican and Democratic colleagues to create a framework designed to help those patients who need it.”
Last week, Florida activists filed a marijuana legalization initiative they hope to place on the 2022 ballot. The move comes after the state Supreme Court invalidated two prior measures the justices deemed to be “misleading.”
Meanwhile, Florida isn’t the only state where psychedelics policy moves are being made.
Jurisdictions across the country are increasingly removing or reducing penalties around drug possession and consumption, especially when it comes to psychedelics. Since Denver in 2019 became the first U.S. city to decriminalize psilocybin mushrooms, a number of states and municipalities have made similar changes to dismantle the drug war.
Oregon voters passed a pair of initiatives last November to legalize psilocybin therapy and decriminalize possession of all drugs. On the local level, activists in Portland are mounting a push to have local lawmakers pass a resolution decriminalizing the cultivation, gifting and ceremonial use of a wide range of psychedelics.
Washington, D.C. voters also approved a ballot measure last year to deprioritize enforcement of laws criminalizing psychedelics.
In California this month, activists were cleared to begin collecting signatures for a historic initiative to legalize psilocybin mushrooms in the state. Oakland and Santa Cruz have already enacted psychedelics decriminalization.
Detroit currently stands to become one of the next major cities to decriminalize psychedelics, with the reform proposal making the local ballot for this November.
Elsewhere in Michigan, the Ann Arbor City Council has already elected to make enforcement of laws prohibition psychedelics like psilocybin, ayahuasca and DMT among the city’s lowest priorities—and lawmakers recently followed up by declaring September Entheogenic Plants and Fungi Awareness Month. Advocates have also introduced a reform resolution to the Grand Rapids City Council.
Massachusetts cities that have enacted the policy change include Northampton, Somerville and Cambridge. In July, state lawmakers heard testimony about a bill to create a task force charged with studying the implications of legalizing psychedelics like psilocybin and ayahuasca.
In Seattle, the City Council is considering a resolution to decriminalize psychedelics.
A New York lawmaker introduced a bill in June that would require the state to establish an institute to similarly research the medical value of psychedelics.
The Maine House of Representatives passed a drug decriminalization bill this year, but it later died in the Senate.
In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.
Meanwhile, Denver activists who successfully led the 2019 campaign to make the city the first in the U.S. to decriminalize psilocybin possession have set their eyes on broader reform, with plans in the works to end the criminalization of noncommercial gifting and communal use of the psychedelic.
In a setback for advocates, the U.S. House of Representatives recently voted against a proposal from Rep. Alexandria Ocasio-Cortez (D-NY) that would have removed a spending bill rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine. However, it picked up considerably more votes this round than when the congresswoman first introduced it in 2019.
Report provisions of separate, House-passed spending legislation also touch on the need to expand cannabis and psychedelics research. The panel urged NIDA to support expanded marijuana studies, for example. It further says that federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions.
There was an attempt by a Republican congressman to attach language into a defense spending bill that would promote research into psychedelics therapy for active duty military members, but it was not made in order in the House Rules Committee this week.
Report provisions of separate, House-passed spending legislation also touch on the need to expand cannabis and psychedelics research. The panel urged NIDA to support expanded marijuana studies, for example. It further says that federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions.
NIDA also recently announced it’s funding a study into whether psilocybin can help people quit smoking cigarettes.
There was an attempt by a Republican congressman to attach language into a defense spending bill that would promote research into psychedelics therapy for active duty military members, but it was not made in order in the House Rules Committee this week.
In May, lawmakers in Congress filed the first-ever legislation to federally decriminalize possession of illicit substances.
Seattle City Council Takes First Step Toward Decriminalizing Psychedelic Plants And Fungi
Photo courtesy of Wikimedia/Workman.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Medical Disclaimer:
The information provided in these blog posts is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The use of any information provided in these blog posts is solely at your own risk. The authors and the website do not recommend or endorse any specific products, treatments, or procedures mentioned. Reliance on any information in these blog posts is solely at your own discretion.
